Actively Recruiting
NAD Augmentation in Diabetes Kidney Disease
Led by Brigham and Women's Hospital · Updated on 2026-04-13
156
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
Sponsors
B
Brigham and Women's Hospital
Lead Sponsor
B
Boston Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.
CONDITIONS
Official Title
NAD Augmentation in Diabetes Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be a man or postmenopausal woman aged 30 years or older
- Have type 1 or type 2 diabetes confirmed by medication use, medical records, HbA1c >6.4%, or fasting glucose >125 mg/dL
- Have two or more morning UACR measurements equal to or above 100 mg/g creatinine, with at least one measured at screening
- If type 2 diabetic with UACR > 300 mg/g creatinine, currently be using an ACE inhibitor, ARB, or SGLT2 inhibitor
- Have an estimated glomerular filtration rate (eGFR) above 25 mL/min/1.73 m2
- Have hemoglobin A1c less than 10%
- Be able to speak English, Spanish, or Haitian Creole
- Be willing and able to provide written informed consent
- Female participants must not be pregnant or planning to become pregnant in the next 6 months
You will not qualify if you...
- Have fasting morning UACR greater than 5,000 mg/g creatinine
- Have liver enzyme (AST or ALT) levels more than 3 times the upper limit of normal
- Have eGFR less than 25 mL/min/1.73 m2
- Have hematocrit less than 0.34 or greater than 0.50 L/L
- Have had a major adverse cardiovascular event in the past 3 months
- Have participated in another drug or biologic trial in the past 3 months or 5 half-lives, whichever is shorter
- Have current alcohol or substance use disorder or dependence
- Have major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms interfering with study procedures
- Have had an acute illness, including COVID-19, requiring hospitalization in the past 3 months or any acute illness in the past month
- Have a history of anaphylaxis from vitamin B3 derivatives
- Have a body mass index (BMI) over 42.5 kg/m2
- Have a confirmed diagnosis of type 3 diabetes or gestational diabetes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
S
Shalender Bhasin, MD
CONTACT
N
Nancy Latham, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here